Reduced Fluence Visudyne-Anti-VEGF-Dexamethasone In Combination for AMD Lesions (RADICAL)
NCT00492284
Completed
The objective of this study is to determine if combination therapy (reduced-fluence Visudyne followed by Lucentis \[within 2 hours\] or either of two regimens of reduced-fluence Visudyne followed by Lucentis-Dexamethasone triple therapy \[within 2 hours\]) reduces retreatment rates compared with Lucentis monotherapy while maintaining similar vision outcomes and an acceptable safety profile.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
05/31/2011
Locations: Not set, Beverly Hills, California +5 locations
Conditions: Choroidal Neovascularization, Macular Degeneration
Register for Updates
Triple Therapy - PDT Plus IVD and Intravitreal Ranibizumab Versus Lucentis Monotherapy to Treat Age-Related Macular Degeneration
NCT00390208
Completed
The purpose of this study is to compare triple therapy using Photodynamic therapy, intravitreal Dexamethasone and intravitreal Ranibizumab injections versus monotherapy with intravitreal Ranibizumab alone for the treatment of Age-Related Macular Degeneration.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
05/25/2010
Locations: Bay Area Retina Associates, Castro Valley, California +1 locations
Conditions: Age Related Macular Degeneration
Register for Updates
Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma
NCT00179647
Completed
Subjects who qualify for participation will receive lenalidomide with or without dexamethasone in 4 week cycles until disease progression is documented or lenalidomide becomes commercially available for the indication of multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2010
Locations: Alta Bates Cancer Center, Berkeley, California +5 locations
Conditions: Multiple Myeloma
Register for Updates
A Study to Evaluate Lenalidomide Combined With Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT00474188
Terminated
To evaluate the safety and efficacy of lenalidomide (Revlimid ®) in combination with dexamethasone in subjects with relapsed or refractory diffuse large B-cell lymphoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/27/2009
Locations: Tower Cancer Research Foundation, Beverly Hills, California
Conditions: Diffuse Large B-cell Lymphoma
Register for Updates
Comparison of Oral Dexamethasone Doses in Asthma Exacerbation
NCT00942201
Completed
Hypothesis: A 2-day course of oral dexamethasone is the superior option for the resolution of symptoms and prevention of relapse in the emergency department (ED) management of mild-moderate asthma exacerbations.
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
07/17/2009
Locations: Rady Children's Hospital, San Diego, California
Conditions: Asthma, Reactive Airway Disease
Register for Updates
Bortezomib, Cyclophosphamide, Dexamethasone, and Thalidomide in Treating Patients With Newly Diagnosed, Previously Untreated Multiple Myeloma
NCT00438841
Unknown
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cyclophosphamide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Thalidomide may stop the growth of cancer cells by blocking blood flow to the cancer. Giving bortezomib together with cyclophosphamide, dexamethasone, and thalidomide may kill more cancer cell... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2009
Locations: Alta Bates Summit Comprehensive Cancer Center, Berkeley, California +3 locations
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Register for Updates